Drugs / HTL0022562
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04941989 | May → Nov 2021 | — | Nxera Pharma UK Limited | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTL0022562 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04941989 ↗ |
| Known as | HTL-22562 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4635331 ↗ |
| Modality | Small molecule | — CHEMBL4635331 ↗ |
| Route | Subcutaneous | “One or more subcutaneous injections of HTL0022562 will be administered.” NCT04941989 ↗ |